Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;4(12):e2137508.
doi: 10.1001/jamanetworkopen.2021.37508.

Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer

Raja Flores  1 , Parth Patel  1 , Naomi Alpert  2 , Bruce Pyenson  3   4 , Emanuela Taioli  2
Affiliations

Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer

Raja Flores et al. JAMA Netw Open. .

Abstract

Importance: Early detection by computed tomography and a more attention-oriented approach to incidentally identified pulmonary nodules in the last decade has led to population stage shift for non-small cell lung cancer (NSCLC). This stage shift could substantially confound the evaluation of newer therapeutics and mortality outcomes.

Objective: To investigate the association of stage shift with population mortality among patients with NSCLC.

Design, setting, and participants: This retrospective cohort study was performed from October 2020 to June 2021 and used data from the Surveillance, Epidemiology, and End Results (SEER) registries to assess all patients from 2006 to 2016 with NSCLC.

Main outcomes and measures: Incidence-based mortality was evaluated by year-of-death. To assess shifts in diagnostic characteristics, clinical stage and histology distributions were examined by year using χ2 tests. Trends were assessed using the average annual percentage change (AAPC), calculated with JoinPoint software. Kaplan-Meier survival analysis assessed overall survival according to stage and compared those missing any stage with those with a reported stage.

Results: The final sample contained 312 382 patients; 166 657 (53.4%) were male, 38 201 (12.2%) were Black, and 249 062 (79.7%) were White; the median (IQR) age was 68 (60-76) years; 163 086 (52.2%) had adenocarcinoma histology. Incidence-based mortality within 5 years of diagnosis decreased from 2006 to 2016 (AAPC, -3.7; 95% CI, -4.1 to -3.4). When assessing stage shift, there was significant association between year-of-diagnosis and clinical stage, with stage I/II diagnosis increasing from 26.5% to 31.2% (AAPC, 1.5; 95% CI, 0.5 to 2.5); and stage III/IV diagnosis decreasing significantly from 70.8% to 66.1% (AAPC, -0.6; 95% CI, -1.0 to -0.2). Missing staging information was not associated with year-of-diagnosis (AAPC, -1.6; 95% CI, -7.4 to 4.5). Year-of-diagnosis was significantly associated with tumor histology (χ2 = 8990.0; P < .001). There was a significant increase in adenocarcinomas: 42.9% in 2006 to 59.0% in 2016 (AAPC, 3.4; 95% CI, 2.9 to 3.9). Median (IQR) survival for stage I/II was 57 months (18 months to not reached); stage III/IV was 7 (2-19) months; and missing stage was 10 (2-28) months. When compared with those with known stage, those without stage information had significantly worse survival than those with stage I/II, with survival between those with stage III and stage IV (log-rank χ2 = 87 125.0; P < .001).

Conclusions and relevance: This cohort study found an association between decreased mortality and a corresponding diagnostic shift from later to earlier stage. These findings suggest that studies investigating the effect of treatment on lung cancer must take into account stage shift and the confounding association with survival and mortality outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Mr Pyenson reported serving as a commissioner on the Medicare Payment Advisory Commission outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Incidence and Incidence-Based Mortality for Non–Small Cell Lung Cancer According to Sex From 2006-2016
AAPC indicates average annual percent change. aThis AAPC value is statistically significant.
Figure 2.
Figure 2.. Shift in Stage at Diagnosis Over Time, 2006-2016
Figure 3.
Figure 3.. Shift in Histology Over Time, 2006-2016
NSCLC indicates non–small cell lung cancer.
Figure 4.
Figure 4.. 10-Year Survival According to Non–Small Cell Lung Cancer Stage at Diagnosis
See this image and copyright information in PMC

References

    1. Henley SJ, Ward EM, Scott S, et al. . Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225-2249. doi:10.1002/cncr.32802 - DOI - PMC - PubMed
    1. Henley SJ, Thomas CC, Lewis DR, et al. . Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers. Cancer. 2020;126(10):2250-2266. doi:10.1002/cncr.32801 - DOI - PMC - PubMed
    1. Jemal A, Thun MJ, Ries LA, et al. . Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672-1694. doi:10.1093/jnci/djn389 - DOI - PMC - PubMed
    1. Henley SJ, Thomas CC, Sharapova SR, et al. . Vital signs: disparities in tobacco-related cancer incidence and mortality - United States, 2004-2013. MMWR Morb Mortal Wkly Rep. 2016;65(44):1212-1218. doi:10.15585/mmwr.mm6544a3 - DOI - PubMed
    1. Howlader N, Forjaz G, Mooradian MJ, et al. . The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640-649. doi:10.1056/NEJMoa1916623 - DOI - PMC - PubMed